Company Profile
Virios Therapeutics Stock Price, News & Catalysts
- Ticker:
- VIRI
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Why the stock is moving
Current closing-price context is not available for VIRI.
Company overview
Non-Opioid Pain Company
Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy.
Halneuron
Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated with chronic opioid treatment.
Long-Term Extension
A Phase 2b extension study evaluates pain reduction over three months of Halneuron treatment after completion of the core four-week study.
SP16
SP16 is an FDA-cleared investigational program for chemotherapy-induced pain and peripheral neuropathy being advanced through an NCI-funded academic study.
Future catalysts
- Topline results from the Phase 2b Halneuron study in chemotherapy-induced neuropathic pain in fall 2026.
- Initiation of the NCI-funded SP16 study in chemotherapy-induced pain and peripheral neuropathy in the second half of 2026.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What does Virios Therapeutics do?
Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy. Halneuron Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated with chronic opioid...
On which exchange is VIRI stock listed?
Virios Therapeutics (VIRI) is associated with NASDAQ, United States, Biopharma.
What is Non-Opioid?
Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy.
Which conditions is Virios Therapeutics targeting with Non-Opioid?
Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy. Halneuron Halneuron is an investigational non-opioid analgesic being evaluated for chemotherapy-induced neuropathic pain. The program is designed to provide durable pain reduction without the risks associated with chronic opioid...
How does Virios Therapeutics describe recent progress with Non-Opioid?
Topline results from the Phase 2b Halneuron study in chemotherapy-induced neuropathic pain in fall 2026. Initiation of the NCI-funded SP16 study in chemotherapy-induced pain and peripheral neuropathy in the second half of 2026.
What is Pain?
Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy.
What should investors watch for with Pain?
Topline results from the Phase 2b Halneuron study in chemotherapy-induced neuropathic pain in fall 2026.
What is Dogwood?
Non-Opioid Pain Company Dogwood Therapeutics, formerly Virios Therapeutics, develops non-opioid medicines for pain and neuropathy.